World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://wjon.elmerpub.com

Original Article

Volume 000, Number 000, July 2025, pages 000-000

Clinicopathological Features of HER2 Expressing Lobular Carcinoma of Breast

Figures

Figure 1.
Figure 1. Histological features of HER2-positive invasive lobular carcinoma. HER2: human epidermal growth factor receptor 2.
Figure 2.
Figure 2. Example of invasive lobular carcinoma overexpressing HER2. (a) H&E × 40. (b) HER2 immunostain showing complete membranous staining, score +3. HER2: human epidermal growth factor receptor 2; H&E: hematoxylin and eosin.
Figure 3.
Figure 3. ER and PRs positive rate (%) comparison between HER2-negative and HER2-overexpressing ILC. ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; ILC: invasive lobular carcinoma; PR: progesterone receptor.

Tables

Table 1. Demographics of HER2+ ILC
 
DemographicsPatients/specimens (n = 28)
HER2: human epidermal growth factor receptor 2; ILC: invasive lobular carcinoma.
Median age (years)54
Stage at presentation (TNM)
  Tumor (T)
    T12 (7.1%)
    T26 (21.4%)
    T37 (25%)
  Metastatic8 (28.5%)
  Unknown5 (17.8%)
  Node (N)
    Nx5 (17.9%)
    N01 (3.6%)
    N11 (3.6%)
    N22 (7.1%)
    N319 (67.9%)
Treatment
  Neoadjuvant chemotherapy with anti-HER211 (39.2%)
  Adjuvant chemotherapy with anti-HER27 (25%)
  Palliative8 (28.6%)
  Unknown2 (7.1%)

 

Table 2. Comparison in Survival Status Between HER2-Negative p-ILC and HER2-Overexpressing ILC
 
StatusHER2-negative p-ILCHER2-overexpressing ILCTotal
Data are expressed as N (Chi-square). HER2: human epidermal growth factor receptor 2; ILC: invasive lobular carcinoma; p-ILC: pleomorphic invasive lobular carcinoma.
Alive without disease8 (0.18)7 (0.15)15
Alive with advanced disease2 (0.21)4 (0.18)6
Dead7 (0.02)9 (0.01)16
Total172037 (grand total)
P-value0.689